Positive Outlook for Pets at Home Amid Regulatory Changes in UK Veterinary Sector

Andrew Wade, an analyst from Jefferies, maintained the Buy rating on Pets at Home (PETS – Research Report). The associated price target remains the same with p325.00.

Andrew Wade has given his Buy rating due to a combination of factors related to the recent developments in the UK veterinary sector. The Competition and Markets Authority (CMA) has released a working paper outlining potential remedies aimed at increasing transparency and regulating pricing within the sector. These measures are expected to focus on making information about prices, treatment options, and services more accessible to consumers.
Wade believes that Pets at Home is well-positioned to handle these changes, as the company is likely to be less affected by the proposed regulatory adjustments. The anticipated reforms include transparency on medicine prices, requirements for generic prescribing, and price controls on certain services, which align with the company’s existing practices. As a result, Wade maintains a positive outlook on Pets at Home’s ability to navigate these industry shifts, supporting his Buy recommendation.

Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PETS in relation to earlier this year.